This secondary analysis of the COMET randomized clinical trial examines patient-reported outcomes at baseline and over time in patients with low-risk ductal carcinoma in situ randomized to receive either active monitoring or guideline-concordant care.
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
The Federal Cervical Cancer Collaborative strives to reduce the burden of cervical cancer for all individuals in the United States through meaningful and culturally appropriate…
Andrew Hantel, MD, and Emily Ray, MD, MPH, discuss presentations in a Thursday afternoon educational session.
The one-year grant of $50,000 supports a postdoctoral or clinical research fellow conducting translational or clinical sarcoma research.
Audio Interview from the New England Journal of Medicine — Interview with Bindu Kanapuru on the FDA’s new expedited withdrawal procedure for accelerated approvals.
Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Patients with intermediate-risk breast cancer had similar rates of 10-year overall survival whether or not they underwent chest wall irradiation (CWI) after mastectomy.
Junjie Li, MD, associate chief physician at Fudan University Shanghai Cancer Center, Shanghai, China, talks with Saba Shaikh, MD, about the HER2-directed ant…
Erik Thiele Orberg, MD, PhD, of University Hospital Regensburg, shares findings of a longitudinal, prospective study investigating microbial and metabolite recovery in the post-transplant period.…
